Table 2.
Medical variables and assessment details of participants with low-grade glioma
| Subtentorial | Supratentorial | |
|---|---|---|
| n = 19 | n = 13 | |
| Age at assessment, y* | ||
| Mean | 12.79 | 15.75 |
| SD | 2.97 | 2.22 |
| Range | 8.42–18.02 | 12.35–19.12 |
| Age at diagnosis, y* | ||
| Mean | 7.22 | 3.86 |
| SD | 3.12 | 2.26 |
| Range | 1.60–12.33 | 1.05–8.41 |
| Time from diagnosis to assessment, y* | ||
| Mean | 5.58 | 11.89 |
| SD | 3.95 | 2.52 |
| Range | 0.59–13.26 | 8.82–16.76 |
| Duration of symptoms, moa | 15.76 | 9.14 |
| Tumor size, mm2b | 2144.33 | 2400.00 |
| Multiple presenting symptoms* | 15 (78.9%) | 4 (21.1%) |
| Surgical outcome/extent of resection* | ||
| Resection >95% | 13 (68.42%) | 2 (15.38%) |
| 50%–95% of tumor resected | 4 (21.05%) | 4 (30.77%) |
| Biopsy | 2 (10.52%) | 1 (7.69%) |
| No surgery | 0 (0.0) | 7 (46.15%) |
| Number of surgeries | ||
| One or less | 17 (89.47%) | 11 (84.61%) |
| Multiple | 2 (11.76%) | 2 (15.38%) |
| Presence of residual symptoms/complications | 10 (52.63%) | 3 (23.07%) |
| Multiple residual symptoms/complications* | 6 (31.58%) | 0 (0%) |
| Hydrocephalus | ||
| Presence of refractory hydrocephalus | 3 (15.79%) | 3 (23.04%) |
| Chemotherapy* | 3 (15.79%) | 7 (53.85%) |
| NF1 status* | 0 (0.0%) | 5 (38.46%) |
aData were unavailable for 2 subtentorial patients and 6 supratentorial patients.
bTumor size was calculated by multiplying the 2 largest measurements of the tumor from anatomical MRI scan. Measurements are in mm2. Tumor size dimensions were not available for 7 subtentorial patients and 12 supratentorial patients. *P < .05.